Catalent finalizes their acquisition of iPSC developer and manufacturer RheinCell Therapeutics.
On August 4th, 2021, Catalent announced that they had finalized the acquisition of RheinCell Therapeutics, a manufacturer and developer of induced pluripotent stem cells (iPSC) technologies. The company had announced their principal agreement to acquire RheinCell on
Founded in 2017, RheinCell research has broad applicability for cell-based therapies. As a stem cell, iSPCs can be differentiated into various cell types, which means they can be used for a variety of different cell therapies.
According to a company press release, RheinCell’s acquisition grants Catalent full good manufacturing practice (GMP) lines, non-GMP equivalent iPSC banks, and iSPC development and reprogramming. Catalent will now have accelerated access to high-quality iSPC banks and the ability to build on their existing iSPC services, among other things.
Source:
